License a precision neuromodulation platform
License a precision neuromodulation platform
Aleva's platform gives partners a shortcut. 100 granted patents across 10+ patent families, MEMS-based electrode architecture built on human clinical data, and over 15 years of neuromodulation know-how, available through structured licensing, tech transfer, or selective co-development.
Aleva's platform gives partners a shortcut. 100 granted patents across 10+ patent families, MEMS-based electrode architecture built on human clinical data, and over 15 years of neuromodulation know-how, available through structured licensing, tech transfer, or selective co-development.
Two core IP clusters
Two core IP clusters
Aleva's portfolio covers the hardware that interfaces with neural tissue, the advanced form factors that extend it, and system-level control and clinician programming workflow. Partners can license one cluster or combine multiple families for broader coverage.
Aleva's portfolio covers the hardware that interfaces with neural tissue, the advanced form factors that extend it, and system-level control and clinician programming workflow. Partners can license one cluster or combine multiple families for broader coverage.
Three high-value frontiers for neuromodulation partners
Three high-value frontiers for neuromodulation partners
Validated in Parkinson's disease and essential tremor. The same architecture extends into adjacent indications where precision and form factor create differentiated value.
Validated in Parkinson's disease and essential tremor. The same architecture extends into adjacent indications where precision and form factor create differentiated value.
From first conversation to
technical onboarding
From first conversation to
technical onboarding
Indicative timeline: initial scoping to signed term sheet, 2 to 4 months. Tech transfer execution, 3 to 6 months, depending on scope.
How Aleva's platform transferred to an external program
How Aleva's platform transferred to an external program
Aleva's platform can be packaged, scoped, transferred, and deployed by a partner with a different commercial footprint and indication focus.
The partner brought commercial infrastructure and indication expertise. Aleva brought the technology license and architecture know-how. The deal covered both IP access and a structured development pathway, proving the platform is a transferable foundation, not a closed internal asset.
Pairing the license with a distribution agreement also shows partnership structures can go beyond pure IP licensing, aligning incentives across development and commercial stages.
Selected technical and commercial details available under NDA.
Aleva's platform can be packaged, scoped, transferred, and deployed by a partner with a different commercial footprint and indication focus.
The partner brought commercial infrastructure and indication expertise. Aleva brought the technology license and architecture know-how. The deal covered both IP access and a structured development pathway, proving the platform is a transferable foundation, not a closed internal asset.
Pairing the license with a distribution agreement also shows partnership structures can go beyond pure IP licensing, aligning incentives across development and commercial stages.
Selected technical and commercial details available under NDA.
What partners are actually acquiring
What partners are actually acquiring
